Articles tagged with T Lymphocytes
Research identifies beneficial changes in immune system during pregnancy, which can lead to new treatment strategies for MS. Women with MS experience a 70% decrease in relapses during the last third of pregnancy, possibly due to epigenetic changes and hormone regulation.
A new study published in Science Advances has found that certain antibodies against the Epstein-Barr virus can mistakenly target the brain and spinal cord, causing damage in multiple sclerosis patients. The research reveals a potential link between EBV infection and MS, with implications for personalized therapies.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Researchers have developed an automated calling algorithm for determining B and T cell clonality from NGS data with greater sensitivity than previous models. The new model increases the assay's sensitivity in detecting clonality, allowing for more accurate diagnosis and monitoring of lymphoproliferative disorders.
Increased expression of Musashi 1 on breast cancer cells has significant implications for understanding dormancy and survival in bone marrow. Msi 1 knockdown led to a reduction in cancer stem cells with undetectable PD-L1, suggesting a potential therapeutic target.
Researchers discovered that gamma delta T cells can effectively combat triple-negative breast cancer by targeting stress-induced molecules and phosphoantigens. Counteracting metabolic changes with zolendronate makes immunotherapy more efficient.
Researchers at NIH have characterized idiopathic CD4 lymphocytopenia, a rare immune deficiency that affects the body's ability to fight off infections. People with severe cases of ICL are at higher risk of acquiring or developing multiple diseases, including cancers and autoimmune disorders.
Researchers at Sanford Burnham Prebys have found a way to revive exhausted T cells, which are crucial for destroying cancerous cells. The new approach targets PSGL-1 protein and slows down T cell exhaustion, significantly reducing tumor growth in mice with immunotherapy-resistant melanoma.
Moffitt researchers develop CAR T cells that target prostate cancer biomarker PSCA, killing cancer cells and preserving bone health. Zoledronate treatment enhances antitumor activity with minimal toxicity.
Research found that specific gut bacteria enhance response to PD-1 checkpoint blockade by altering immune molecules PD-L2 and RGMb. This leads to improved detection and destruction of cancer cells, offering potential for enhanced immunotherapy treatment outcomes.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
Researchers at Moffitt Cancer Center found that tumor-associated macrophage clustering in the stromal compartment is associated with poor outcomes. The study developed a score based on gene expression to predict macrophage clustering, which also predicted disease stage and survival.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Researchers found that neutrophils activated by T cell-based immunotherapy can kill tumor cells that evade targeted therapies. This unexpected antitumor response could lead to new immunotherapies that harness this potent immune mechanism.
Studies found that certain T cells in human blood can produce acetylcholine, regulating blood pressure and inflammation. Higher levels of these immune cells were associated with reduced risk of death in seriously ill patients.
Researchers found that immune checkpoint inhibitors increase the mobilization of overlapping tumor-reactive CD8+ T cells, leading to antitumor effects. The diverse subset of T-cell clones plays a key role in this response, with polyclonal clones exhibiting more proliferative potential and contributing to effective treatment outcomes.
Researchers at the University of Wisconsin-Madison have identified a specific cell population, called CD4/CD8 double positive T cells, that causes graft-versus-host disease in bone marrow transplants. The team's findings may lead to targeted treatments and improved patient outcomes.
The study successfully generated functional patient-specific T-cells and thymic epithelial cells from human pluripotent stem cells using thymus organoids. This breakthrough provides a new experimental model system to investigate thymic insufficiency and function, potentially leading to cell-based treatments for thymic defects.
Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.
A comprehensive analysis of invasive ER+ breast cancers found macrophages as dominant immune cells infiltrating tumors. The study identified distinct immune cell 'neighborhoods' associated with good patient outcomes and highlights the need for tailored immunotherapies targeting macrophages.
A study by Washington University School of Medicine suggests targeting T cells to prevent neurodegeneration and treat Alzheimer's disease. The research indicates that microglia partner with T cells to cause brain damage in the disease, and blocking their entry can avoid most neurodegeneration.
A new study discovered that maternal γδ T cells influence the transfer of microorganisms during birth and nursing, impacting lung immune response in newborns. This discovery highlights the role of gut microbiota in modulating lung immunity and has implications for understanding the first breath response.
A study published in the Journal of Biological Chemistry found that a fish oil derivative called DHEA can reduce inflammation and disease severity in mice with multiple sclerosis. By supplementing the diet of mice with DHEA, researchers noticed a decrease in MS-like disease symptoms and an improvement in the immune system's response.
A team of scientists led by Thomas Blankenstein presents a mechanism that prevents the immune response from overshooting its mark. The KRKR motif, a short sequence of four amino acids, is crucial in binding to connective tissue and preventing interferon-gamma from spreading throughout the body.
A new Pitt study reframes understanding of graft-versus-host disease, suggesting that GVHD is locally maintained by donor T cells in target tissues. The research, published in Immunity, offers an alternative model that could guide development of novel therapies and improve outcomes for stem cell recipients.
Researchers found that certain gene signaling pathways, such as interferon γ and beta-catenin, can lead to tumor hyperprogression after immunotherapy. Targeting these pathways may prevent hyperprogression in preclinical models.
Researchers from Hospital Universitario 12 de Octubre and Josep Carreras Institute create a cell therapy based on STAb cells for T-Cell Acute Lymphoblastic Leukemia (T-ALL), a rare disease with few treatment options. The new therapy offers an alternative to CAR-T therapies, which have limitations in treating this type of leukemia.
Researchers have discovered a new biomarker that predicts the response to CAR-T cell therapy in patients with diffuse large B cell lymphoma. The biomarker identifies differentiated T cells, which can be removed from leukemia products to improve therapy success rates.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
Research from Michigan Medicine reveals that high levels of ammonia in colon tumors can lead to reduced T cell growth and immunotherapy resistance. A study published in Cell Metabolism found that using an FDA-approved drug to lower ammonia levels made tumors more sensitive to treatment.
A study published in Cancer Research found that the stress response in T cells can hinder cancer immunotherapy. The researchers discovered that targeting key proteins involved in this stress response could help develop more potent cancer immunotherapies.
Scientists at UCSF have engineered T cells to produce a potent anti-cancer cytokine that only activates in tumor cells, eliminating melanoma and pancreatic cancer in mice. The treatment uses IL-2, which supercharges T cells to kill cancer cells while protecting against infection, offering a promising new strategy for fighting hard-to-t...
Researchers at La Jolla Institute for Immunology have found that the inflammatory molecule LIGHT leads to airway remodeling and long-term breathing issues in severe asthma. Therapeutics targeting LIGHT could reverse airway and lung damage, offering a potential long-term treatment for asthma.
Researchers develop new method to identify crucial protein fragments driving autoimmunity, enabling better diagnostics and therapies. The study finds cross-reactivity between human and microbial proteins drives autoimmunity in at least two diseases.
A team of researchers discovered that the gut microbiome plays a critical role in driving granulopoiesis, a process formation of granulocytes, in mice models. The study found that alterations in the gut microbiome composition induced by neutropenia stimulate reactive granulopoiesis via interleukin 17A secreted by T cells, promoting neu...
The study reveals that coronin proteins regulate T cell population size by promoting survival signals when cells are not too crowded. This mechanism is evolutionarily conserved in both humans and slime molds, opening up new avenues for research.
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
Researchers found that immune checkpoint blockade therapy may be beneficial for certain cases of severe COVID-19. In pre-clinical trials, treatment with a PD-1 inhibitor restored T cell functionality and reduced inflammation in mice infected by MHV-A59, another betacoronavirus.
Researchers found that two-dose CoronaVac vaccination schedules, spaced 2 or 4 weeks apart, elicit similar immune responses against SARS-CoV-2 variants. The study suggests that either schedule can provide equal protection against COVID-19.
Researchers at the University of Bonn have identified a mechanism that helps dendritic cells migrate more quickly to lymph nodes. The discovery reveals that forming multiple centrosomes enables these immune cells to stay on course longer before continuing their search.
A novel COVID-19 vaccine developed by Brazilian scientists combines two SARS-CoV-2 proteins to trigger a cellular immune response. The vaccine, called SpiN, showed promise in animal trials, protecting against three strains of the virus and reducing viral load by up to 50 times.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
A new intracellular checkpoint gene, CISH, has been found to suppress the ability of human T-cells to recognize and attack cancer cells. When CISH is disabled, T-cells more effectively recognize mutated proteins produced by tumors, making them more responsive to existing checkpoint therapies.
A study by researchers at Linköping University suggests that severe COVID-19 infection has long-lasting negative effects on the immune system. The results showed that patients developed antibodies against SARS-CoV-2 within 2-3 weeks of symptoms, which then started to fall after six months.
Researchers at LSU Health New Orleans have identified a critical immunosuppressive pathway and developed an experimental inhibitor to protect T-cells from weakening. The CBL-B inhibitors show great potential in enhancing the efficacy of cancer immunotherapy, making patients' T-cells more effective in killing cancer cells.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
A new study identifies PDIA3 as a molecule targeted by the immune system in response to stress, contributing to liver damage in type 2 diabetes and obesity. Elevated levels of antibodies for PDIA3 have been found in people with these conditions, but improving diet and weight can reverse this liver condition.
Researchers captured first image of antigen-bound T-cell receptor complex with bound antigen at atomic resolution. The study reveals no significant structural changes in the receptor after antigen binding, sparking further investigation into the signaling pathway activation mechanism.
Researchers at Terasaki Institute create micro-organospheres for direct viral infection, immune cell penetration, and high-throughput therapeutic drug screening. The technology holds promise for personalized medicine, tumor therapy and rapid drug testing.
Researchers found that immune cells prefer nutrient fuels previously thought to be waste products, including lactate. This discovery could lead to personalized dietary recommendations to supercharge the immune system. The findings also suggest a strong influence of nutrients on T cell function and survival.
Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.
A new study from Tel Aviv University found that CRISPR therapeutics can lead to a significant loss of genetic material in treated cells, potentially destabilizing the genome and promoting cancer. The researchers detected up to 10% of cells with lost chromosomes, highlighting the need for extra care when using this technology.
Research reveals T cells in colorectal cancer have a double-edged function. Initially protective against tumor growth, they later promote cancer progression by altering their receptors and producing pro-inflammatory cytokines. The study offers new insights into the role of T cells in colorectal cancer and potential avenues for therapy.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Studies in rats have found that T-cells produce reactive oxygen species (ROS) that contribute to preeclampsia complications. Researchers are exploring ways to dampen this response to reduce the risk of premature birth or worse outcomes for mother and child.
The study reveals how the protein binds to ligands and inhibitory antibodies, providing insights into its molecular function. The findings may lead to better targeted therapeutic approaches in the future.
The University of Houston research team has successfully developed a method for 3D printing organic semiconductor devices using multiphoton lithography, enabling the creation of highly conductive microstructures. The technology has potential applications in emerging fields such as nanoelectronics and bioelectronics.
Researchers at the University of Birmingham have identified a 'cellular brake' protein that may help prevent autoimmune responses in lung cancer patients undergoing immunotherapy treatment. This finding could enable clinicians to closely monitor high-risk patients and develop preventative strategies.
A new study found that patients with long COVID have virus-specific T cell levels over 100 times higher than those who recovered from the disease. The research team's findings suggest hidden viral reservoirs may be causing long-term symptoms, guiding future treatments towards vaccines and antiviral medications.
A new study by Gladstone Institutes and UC San Francisco found that infection with the Omicron variant provides weak immune response in unvaccinated individuals, failing to confer broad protection against other variants. In contrast, vaccinated individuals show stronger immunity against multiple COVID-19 strains.